Eligen insulin - A system for the oral delivery of insulin for diabetes

IDrugs

Volumn 11, Issue 6, 2008, Pages 433-441

  Hoffman, A ^a   Qadri, B ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(2 HYDROXY 4 CHLOROBENZOYL)AMINO]BUTANOATE SODIUM; DRUG CARRIER; GLUCOSE; INSULIN; METFORMIN; N 8 [2 (HYDROXYBENZOYL)AMINO]CAPRYLATE SODIUM;

BEDTIME DOSAGE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TOLERABILITY; EVENING DOSAGE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; MONOTHERAPY; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TREATMENT CONTRAINDICATION; TREATMENT FAILURE;

CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DIABETES MELLITUS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 44449086871     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. 296266 Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. Damge C, Vranckx H, Balschmidt P, Couvreur P J PHARM SCI 1997 86 12 1403-1409
2. 413533 Emisphere initiates clinical testing of oral insulin. Emisphere Technologies Inc PRESS RELEASE 2001 June 25
3. 414535 New oral formulation of human insulin. Kidron M, Mizrachi Y, Baron H, Variano B DIABETES 2001 50 Suppl 6 1833-PO
4. 417019 Emisphere Technologies announces second-quarter results for 2001. Emisphere Technologies Inc PRESS RELEASE 2001 July 26
5. 421599 Emisphere reports results from three oral insulin studies. Emisphere Technologies Inc PRESS RELEASE 2001 September 07
6. 454048 Oral insulin: Pharmacokinetics and pharmacodynamics of human insulin following oral administration of an insulin/delivery agent capsule in healthy volunteers. Abbas R, Leone-Bay A, Agawal RK, Majuru S, Rolan P, Clarke S, Arbit E, Baughman RA DIABETES 2002 51 2 A197-OR
7. 454050 The effects of timing of a standardized meal on absorption of a single oral dose of hexyl-insulin monoconjugate (HIM2) in patients with type 1 diabetes. Clement S, Still JG, Kosutic G DIABETES 2002 51 2 A198-OR
8. 454283 A novel per-oral insulin formulation for human subjects. Kidron M, Menachem Y, Variano B, Arbit E, Dinh S, Goldberg M, Bar-on H DIABETES 2002 51 2 A526-P
9. 457234 Oral delivery of insulin using pH-responsive complexation gels. Lowman AM, Morishita M, Kajita M, Nagai T, Peppas NA J PHARM SCI 1999 88 9 933-937
10. 463303 Protein and peptide formulation strategies for drug development and delivery. Cipolla D IDDB MEETING REPORT 2002 August 19-20
11. 479207 Oral delivery of protein and peptide therapeutic molecules: Overview. Dinh S SMI CONFERENCE - CONTROLLED RELEASE 2003 February 12-13
12. 492745 Oral insulin: Proof of concept in type 2 diabetic patients. Kapitza C, Arbit E, Abbas R, Goldberg M, Hompesch M, Heinemann L, Heise T DIABETES 2003 52 Suppl 6 Abs 159-OR
13. 520456 Positive phase II data for Emisphere's oral insulin. Emisphere Technologies Inc PRESS RELEASE 2004 January 29
14. 523397 Oral delivery of protein drugs. Dinh S SMI CONFERENCE - CONTROL RELEASE 2004 10 Feb
15. 526526 Controlled Release - Third Annual SMi Conference. Phillips T IDRUGS 2004 7 3 235-237
16. 526656 Beneficial effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents. Guevara-Aguirre J, Guevara M, Saavedra J, Mihic M, Modi P DIABETES TECHNOL THER 2004 6 1 1-8
17. 527909 Alternative routes of insulin delivery. Owens DR, Zinman B, Bolli G DIABETIC MED 2003 20 11 886-898
18. 573581 Oral spray insulin in treatment of type 2 diabetes: A comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (sc) insulin injection, a proof-of-concept study. Guevara-Aguirre J, Guevara M, Saavedra J, Mihic M, Modi P DIABETES-METAB RES REV 2004 20 6 472-478
19. 606259 Reduction of postprandial blood glucose excursions by an optimized formulation of oral insulin. Heise T, Nosek L, Arbit E, Beckett P, Gelfand R, Porter KM, Goldberg M, Kapitza C DIABETES 2005 54 6 Suppl 1 Abs 418-P
20. 633059 A novel per-oral insulin formulation: Proof-of-concept study in non-diabetic subjects. Kidron M, Dinh S, Menachem Y, Abbast R, Variano B, Goldberg M, Arbit E, Bar-On H DIABETIC MED 2004 21 4 354-357
21. 633067 Immediate and short-term cellular and biochemical responses to pulmonary single-dose studies of insulin and H-MAP. Garcia-Contreras L, Sarubbi D, Flanders E, O'Toole D, Smart J, Newcomer C, Hickey AJ PHARM RES 2001 18 12 1685-1693
22. 633068 Facilitation of pulmonary insulin absorption by H-MAP: Pharmacokinetics and pharmacodynamics in rats. Suarez S, Garcia-Contreras L, Sarubbi D, Flanders E, O'Toole D, Smart J, Hickey AJ PHARM RES 2001 18 12 1677-1684
23. 633073 Oral delivery of insulin with the Eligen technology: Mechanistic studies. Malkov D, Angelo R, Wang H-Z, Flanders E, Tang H, Gomez-Orellana I CURR DRUG DELIV 2005 2 2 191-197
24. 639078 Generex Biotechnology announces launch of Oral-lyn non-injectable insulin soon available to patients for the first time. Generex Biotechnology Corp PRESS RELEASE 2005 December 06
25. 661297 Emisphere to expand Indian phase II diabetes trial. Emisphere Technologies Inc PRESS RELEASE 2006 April 11
26. 672831 Pharmacokinetics (PK) and pharmacodynamics (PD) of insulin/4-CNAB administered prior to and following a high-calorie, high-fat meal in type 2 diabetic subjects. Kidron M, Castelli C, Beckett P, Porter K, Bhaskar S, Bar-On H, Goldberg M, Arbit E DIABETES 2006 55 6 Suppl 1 417P
27. 736260 Emisphere Technologies demonstrates safety and efficacy of oral insulin in phase 2 trial in type 2 diabetics. Emisphere Technologies Inc PRESS RELEASE 2006 October 30
28. 740229 Emisphere reports additional clinical data from phase 2 oral insulin trial. Emisphere Technologies Inc PRESS RELEASE 2006 November 08
29. 792880 AutoImmune Inc reports 2007 first-quarter financial results. AutoImmune Inc PRESS RELEASE 2007 May 10
30. 793219 NCT00419562: Oral insulin for prevention of diabetes in relatives at risk for type 1 diabetes mellitus. National Institutes of Health CLINICALTRIALS.GOV 2007 February 05
31. 803109 Drug Delivery 2007 - New technologies, partnering and strategies for the future. Stevenson L IDRUGS 2007 10 6 388-390
32. 833427 Nastech starts phase II trial of intranasal insulin. Nastech Pharmaceutical Co Inc PRESS RELEASE 2007 September 26
33. 840724 Pfizer reports third-quarter 2007 results; reconfirms 2007 and 2008 revenue and adjusted diluted EPS(1) Guidance. Pfizer Inc PRESS RELEASE 2007 October 18
34. 846624 Generex's Oral-lyn approved in India for diabetes. Generex Biotechnology Corp PRESS RELEASE 2007 November 01
35. 884545 Generex Biotechnology comments on recent trading activity. Generex Biotechnology Corp PRESS RELEASE 2008 March 10
36. 887044 Emisphere Technologies Inc announces 2007 fourth quarter and year-end financial results. Emisphere Technologies Inc PRESS RELEASE 2008 March 17
37. 894246 The internal secretion of the pancreas. 1922. Banting FG, Best CH INDIAN J MED RES 2007 125 3 251-266
38. 894248 Concept, strategies and feasibility of non-invasive insulin delivery. Cefalu WT DIABETES CARE 2004 27 1 239-246
39. 894249 Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, Ferrannini E, DeFronzo RA J CLIN INVEST 1989 84 1 205-213
40. 894251 Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Rizza RA, Mandarino LJ, Gerich JE AM J PHYSIOL 1981 240 6 E630-E639
41. 894252 Physiological consequences of phasic insulin release in the normal animal. Cherrington AD, Sindelar D, Edgerton D, Steiner K, McGuinness OP DIABETES 2002 51 Suppl 1 S103-S108
42. 894256 The physiological rationale for oral insulin administration. Arbit E DIABETES TECHNOL THER 2004 6 4 510-517
43. 894257 Use of liposomes to aid intestinal absorption of entrapped insulin in normal and diabetic dogs. Patel HM, Stevenson RW, Parsons JA, Ryman BE BIOCHIM BIOPHYS ACTA 1982 716 2 188-193
44. 894274 Investigation of the enhancing mechanism of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate effect on the intestinal permeability of polar molecules utilizing a voltage clamp method. Hess S, Rotshild V, Hoffman A EUR J PHARM SCI 2005 25 2-3 307-312
45. 894831 Nektar terminates inhaled insulin programs as Exubera linked to increased lung cancer risk. Nektar Therapeutics PRESS RELEASE 2008 April 09
46. 895623 The discovery of insulin. THE DISCOVERY OF INSULIN 1982 1-304
47. 895625 The absorption of insulin from the intestine in dogs. Kidron M, Krausz MM, Raz I, Bar-0n H, Ziv E TENSIDE SURF DET 1989 26 352-354
48. 899003 Biocon Group delivers healthy performance for FY 2007-08. Biocon Ltd PRESS RELEASE 2008 April 22
49. 903355 The development of delivery agents that facilitate the oral absorption of macromolecular drugs. Leone-Bay A, Paton DR, Weidner JJ MED RES REV 2000 20 2 169-186
50. 903358 Absorption of insulin from the human small intestine. Crane CW, Luntz GR DIABETES 1968 17 10 625-627
51. 903386 Challenges for the oral delivery of macromolecules. Goldberg M, Gomez-Orellana I NAT REV DRUG DISCOV 2003 2 4 289-295
52. 903565 Evolution of a pulmonary insulin delivery system (Exubera) for patients with diabetes. Barnett AH, Bellary S VASC HEALTH RISK MANAG 2007 3 1 83-91
53. 903574 Current challenges in non-invasive insulin delivery systems: A comparative review. Khafagy el-S, Morishita M, Onuki Y, Takayama K ADV DRUG DELIV REV 2007 59 15 1521-1546
54. 903616 Product information: Emisphere's oral insulin program. Emisphere Technologies Inc COMPANY WORLD WIDE WEB SITE 2008 April 17
55. 903617 Product information: Eligen technology. Emisphere Technologies Inc COMPANY WORLD WIDE WEB SITE 2008 April 18
56. 903723 Case study: A phase IIb trial in type II diabetic patients. iGate Clinical Research International COMPANY PUBLICATION 2008 March 02